| 词条 | Chugai Pharmaceutical Co. |
| 释义 |
| name = Chugai Pharmaceutical, 中外 | logo = Chugai Pharmaceutical.svg | type = Public (K.K) | traded_as = {{tyo|4519}} | industry = Pharmaceutical Industry, Business import, production and development of drugs for medical sales | founded = 1943 March 8 | location = Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) | key_people = Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO | revenue = 72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007) | homepage = {{url|www.chugai-pharm.co.jp}} (in Japanese) }}{{nihongo|Chugai Pharmaceutical Co., Ltd.|中外製薬株式会社|Chūgai Seiyaku Kabushikigaisha}} is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. History
Other notable developmentsScientists at Chugai discovered an erythromycin-derived motilin agonist called mitemcinal (GM-611 or 3′-N-dimethyl-11-deoxy-3′-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin). Mitemcinal was believed to have strong prokinetic properties, like its parent molecule, but lack antibiotic properties. Presently, erythromycin is commonly used off-label for gastric motility indications such as gastroparesis. If mitemcinal can be shown to be as effective a prokinetic agent, it would represent an advance in the field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria. See also
References1. ^{{cite news|url=https://www.bloomberg.com/news/2014-08-24/roche-said-to-have-decided-against-bid-for-rest-of-chugai.html|title=Roche Said to Have Decided Against Bid for Rest of Chugai|first=Michelle Fay|date=25 August 2014|last2=Matsuyama|first2=Kanoko|agency=Bloomberg|author=Cortez}} 2. ^{{Cite journal|last=Staff|date=2 March 2015|title=Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership|url=http://www.genengnews.com/gen-news-highlights/chugai-to-co-develop-athersys-cell-therapy-in-japan-in-up-to-205m-partnership/81250978/|journal=Genetic Engineering & Biotechnology News|type=Paper, Vol 35, i 7, p. 12|access-date=2016-06-11}} External links
3 : Hoffmann-La Roche|Pharmaceutical companies of Japan|Companies listed on the Tokyo Stock Exchange |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。